skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 379  for All Library Resources

Sorted by: Sorted by: PopularityOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Database: GFMER Free Medical Journals remove language: Russian remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Total DNA methylation in the brain in response to decitabine treatment in female rats
Total DNA methylation in the brain in response to decitabine treatment in female rats
Material Type:
Article 		Add to My Research

Total DNA methylation in the brain in response to decitabine treatment in female rats

Acta Facultatis Pharmaceuticae Universitatis Comenianae, 2019-06, Vol.66 (1), p.1-3 [Peer Reviewed Journal]

2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2453-6725 ;ISSN: 0301-2298 ;EISSN: 2453-6725 ;EISSN: 1338-6786 ;DOI: 10.2478/afpuc-2019-0005

Full text available

Citations Cited by
2
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Material Type:
Article 		Add to My Research

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2046-2054 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.38.4032 ;PMID: 22547592

Full text available

Citations Cited by
3
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Material Type:
Article 		Add to My Research

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.44.2806 ;PMID: 23816960

Full text available

Citations Cited by
4
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
Material Type:
Article 		Add to My Research

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2055-2062 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.39.5848 ;PMID: 22547591

Full text available

Citations Cited by
5
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Material Type:
Article 		Add to My Research

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3499-3506 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.42.8201 ;PMID: 22949147

Full text available

Citations Cited by
6
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Material Type:
Article 		Add to My Research

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3517-3524 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.48.4410 ;PMID: 23980084

Full text available

Citations Cited by
7
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
Material Type:
Article 		Add to My Research

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Journal of clinical oncology, 2013-08, Vol.31 (24), p.3004-3011 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;ISSN: 1527-7755 ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.42.3749 ;PMID: 23835708

Full text available

Citations Cited by
8
Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial
Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial
Material Type:
Article 		Add to My Research

Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial

Journal of the American College of Cardiology, 2013-12, Vol.62 (24), p.2318-2325 [Peer Reviewed Journal]

2015 INIST-CNRS ;Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2013.06.053 ;PMID: 23973694 ;CODEN: JACCDI

Full text available

Citations Cited by
9
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4105-4114 [Peer Reviewed Journal]

2015 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.47.4189 ;PMID: 24101053

Full text available

Citations Cited by
10
Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002
Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002
Material Type:
Article 		Add to My Research

Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002

Journal of clinical oncology, 2014-01, Vol.32 (3), p.174-184 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2013.48.6522 ;PMID: 24344215

Full text available

Citations Cited by
11
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Material Type:
Article 		Add to My Research

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Journal of clinical oncology, 2013-10, Vol.31 (30), p.3791-3799 [Peer Reviewed Journal]

2014 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.47.4940 ;PMID: 24019545

Full text available

Citations Cited by
12
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
Material Type:
Article 		Add to My Research

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

Annals of oncology, 2010-08, Vol.21 (8), p.1712-1717 [Peer Reviewed Journal]

2010 European Society for Medical Oncology ;2015 INIST-CNRS ;ISSN: 0923-7534 ;ISSN: 1569-8041 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdq013 ;PMID: 20147741

Full text available

Citations Cited by
13
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Material Type:
Article 		Add to My Research

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1227-1234 [Peer Reviewed Journal]

2009 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2007.14.5466 ;PMID: 19188680

Full text available

Citations Cited by
14
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Material Type:
Article 		Add to My Research

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2128-2135 [Peer Reviewed Journal]

2014 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.43.7251 ;PMID: 23650416

Full text available

Citations Cited by
15
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Material Type:
Article 		Add to My Research

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1252-1260 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.28.0982 ;PMID: 21383283

Full text available

Citations Cited by
16
Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium
Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium
Material Type:
Article 		Add to My Research

Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium

American journal of epidemiology, 2013-09, Vol.178 (5), p.679-690 [Peer Reviewed Journal]

2014 INIST-CNRS ;Copyright Oxford Publishing Limited(England) Sep 1, 2013 ;The Author 2013. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2013 ;ISSN: 0002-9262 ;EISSN: 1476-6256 ;DOI: 10.1093/aje/kwt029 ;PMID: 23817919 ;CODEN: AJEPAS

Full text available

Citations Cited by
17
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Material Type:
Article 		Add to My Research

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4485-4491 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.28.9066 ;PMID: 20697094

Full text available

Citations Cited by
18
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
Material Type:
Article 		Add to My Research

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Annals of oncology, 2014-07, Vol.25 (7), p.1340-1346 [Peer Reviewed Journal]

2014 THE AUTHORS ;2015 INIST-CNRS ;The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. ;The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 2014 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdu110 ;PMID: 24608196

Full text available

Citations Cited by
19
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Material Type:
Article 		Add to My Research

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of clinical oncology, 2013-01, Vol.31 (2), p.195-202 [Peer Reviewed Journal]

2014 INIST-CNRS ;2012 by American Society of Clinical Oncology 2012 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.38.3331 ;PMID: 23233719

Full text available

Citations Cited by
20
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Material Type:
Article 		Add to My Research

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2259-2266 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2009.26.0638 ;PMID: 20368561

Full text available

Citations Cited by

Results 1 - 20 of 379  for All Library Resources

Sorted by: Sorted by: PopularityOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1989  (8)
  2. 1989 To 1996  (16)
  3. 1997 To 2003  (79)
  4. 2004 To 2011  (193)
  5. After 2011  (84)
  6. More options open sub menu

Language 

  1. English  (372)
  2. Japanese  (79)
  3. German  (15)
  4. Slovak  (15)
  5. Czech  (15)
  6. Portuguese  (1)
  7. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait